2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
ESC Scientific Document Group
(2022) European heart journal, volume 43, issue 41, pp. 4229 - 4361
(Article)
Download/Full Text
The full text of this publication is not available.
Keywords: Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Anthracycline, Arrhythmias, Atrial fibrillation, Biomarkers, Cancer, Cancer survivors, Carcinoid syndrome, Cardiac magnetic resonance, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Coronary artery disease, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Strain, Thrombosis, Trastuzumab, Valvular heart disease, Vascular endothelial growth factor inhibitors (VEGFi), Venous thromboembolism, Cardiology and Cardiovascular Medicine
ISSN: 0195-668X
Publisher: Oxford University Press
Note: Funding Information: ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.
(Peer reviewed)